[Skip to Content]
[Skip to Content Landing]

Red Blood Cell Transfusion2023 AABB International Guidelines

To identify the key insights or developments described in this article
1 Credit CME
Abstract

Importance  Red blood cell transfusion is a common medical intervention with benefits and harms.

Objective  To provide recommendations for use of red blood cell transfusion in adults and children.

Evidence Review  Standards for trustworthy guidelines were followed, including using Grading of Recommendations Assessment, Development and Evaluation methods, managing conflicts of interest, and making values and preferences explicit. Evidence from systematic reviews of randomized controlled trials was reviewed.

Findings  For adults, 45 randomized controlled trials with 20 599 participants compared restrictive hemoglobin-based transfusion thresholds, typically 7 to 8 g/dL, with liberal transfusion thresholds of 9 to 10 g/dL. For pediatric patients, 7 randomized controlled trials with 2730 participants compared a variety of restrictive and liberal transfusion thresholds. For most patient populations, results provided moderate quality evidence that restrictive transfusion thresholds did not adversely affect patient-important outcomes. Recommendation 1: for hospitalized adult patients who are hemodynamically stable, the international panel recommends a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (strong recommendation, moderate certainty evidence). In accordance with the restrictive strategy threshold used in most trials, clinicians may choose a threshold of 7.5 g/dL for patients undergoing cardiac surgery and 8 g/dL for those undergoing orthopedic surgery or those with preexisting cardiovascular disease. Recommendation 2: for hospitalized adult patients with hematologic and oncologic disorders, the panel suggests a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (conditional recommendations, low certainty evidence). Recommendation 3: for critically ill children and those at risk of critical illness who are hemodynamically stable and without a hemoglobinopathy, cyanotic cardiac condition, or severe hypoxemia, the international panel recommends a restrictive transfusion strategy considering transfusion when the hemoglobin concentration is less than 7 g/dL (strong recommendation, moderate certainty evidence). Recommendation 4: for hemodynamically stable children with congenital heart disease, the international panel suggests a transfusion threshold that is based on the cardiac abnormality and stage of surgical repair: 7 g/dL (biventricular repair), 9 g/dL (single-ventricle palliation), or 7 to 9 g/dL (uncorrected congenital heart disease) (conditional recommendation, low certainty evidence).

Conclusions and Relevance  It is good practice to consider overall clinical context and alternative therapies to transfusion when making transfusion decisions about an individual patient.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 26, 2023.

Published Online: October 12, 2023. doi:10.1001/jama.2023.12914

Corresponding Author: Jeffrey L. Carson, MD, Department of Medicine, Rutgers Robert Wood Johnson Medical School, 125 Paterson St, New Brunswick, NJ 08901 (jeffrey.carson@rutgers.edu).

Author Contributions: Drs Carson and Stanworth had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Carson, Stanworth, Guyatt, Valentine, Bakhtary, Cohn, Grossman, Kaplan, Prochaska, Wood, Pagano.

Acquisition, analysis, or interpretation of data: Carson, Stanworth, Guyatt, Dennis, Bakhtary, Cohn, Dubon, Grossman, Gupta, Hess, Jacobson, Kaplan, Lin, Metcalf, Murphy, Pavenski, Prochaska, Raval, Salazar, Saifee, Tobian, So-Osman, Waters, Zantek, Pagano.

Drafting of the manuscript: Carson, Stanworth, Valentine, Dennis, Kaplan, Murphy, Prochaska, Waters, Pagano.

Critical review of the manuscript for important intellectual content: Dennis, Dubon, Hess, Metcalf, Pavenski, Raval, Salazar, Zantek.

Statistical analysis: Carson, Stanworth, Dennis, Hess, Pagano.

Obtained funding: Cohn.

Administrative, technical, or material support: Carson, Valentine, Dennis, Cohn, Hess, Salazar, Tobian, Wood, Pagano.

Supervision: Carson, Stanworth, Guyatt, Cohn, Prochaska, Raval, Waters, Pagano.

Patient perspective: Dubon.

Served as guideline development panelist: Pavenski.

Representative of the International Society of Blood Transfusion: Wood.

Clinical content expert and European representative: So-Osman.

Other: Kaplan, Prochaska.

Part of the committee involved in the guidelines drafting, review, and discussion: Salazar.

Conflict of Interest Disclosures: Dr Carson reported serving as chair of the data and safety monitoring board for Cerrus for a clinical trial on a treatment system to pathogen-reduce human blood products outside the submitted work; being the principal investigator of a National Heart, Lung, and Blood Institute–supported trial called Myocardial Ischemia and Transfusion, which is evaluating transfusion thresholds in patients with acute myocardial infarction; and receiving financial support paid to his institution. Dr Stanworth reported receiving grants for multiple clinical trials of red blood cell transfusion to his institution, but no direct financial benefits outside the submitted work; receiving grants for red blood cell transfusion trials through his institutions; and being employed by NHSBT, who processes and manufactures red blood cells for transfusion in England. Dr Cohn reported being a paid staff member (chief medical officer) of the AABB during the conduct of the study. Dr Kaplan reported receiving a stipend from the Society of Critical Care Medicine for serving as president from 2020 to 2021 outside the submitted work. Dr Lin reported receiving grants from Canadian Blood Services, consulting for Choosing Wisely Canada, and receiving grants from Octapharma outside the submitted work. Dr Metcalf reported receiving speakers honoraria from Cerus Corporation outside the submitted work. Dr Pavenski reported serving as vice chair of the International Collaboration for Transfusion Medicine Guidelines and as director for North Americas, as well as serving on the board of directors for the International Society of Blood Transfusion. Dr Prochaska reported receiving fees for medicolegal consulting outside the submitted work. Dr Raval reported receiving consultancy fees from Sanofi Genzyme outside the submitted work. Dr Saifee reported nonfinancial support from AABB for travel during the conduct of the study. Dr Zantek reported receiving fees from the Association for the Advancement of Blood and Biotherapies for travel to a meeting for guideline development during the conduct of the study; that her spouse is an employee of Boston Scientific and has financial interest in the company and in ENDO International outside the submitted work; and serving on the board of directors for the American Society for Apheresis, BloodNet, External Quality Assurance in Thrombosis and Hemostasis, and the North American Specialized Coagulation Laboratory Association. No other disclosures were reported.

Funding/Support: Support for guideline development was provided by AABB, Bethesda, Maryland; and international partner organizations.

Additional Contributions: Maria-Helini Trivella, PhD (London School of Hygiene and Tropical Medicine), provided statistical advice without compensation. Panel and Guideline Group members: The panel included current or former members of the AABB Clinical Transfusion Medicine Committee (Jeffrey L. Carson, MD, Sara Bakhtary, MD, Claudia S. Cohn, MD, PhD, Brenda J. Grossman, MD, MPH, Gaurav K. Gupta, MD, PhD, Aaron S. Hess, MD, PhD, Jessica L. Jacobson, MD, Ryan A. Metcalf, MD, Colin H. Murphy, MD, Micah T. Prochaska, MD, Jay S. Raval, MD, Eric Salazar, MD, PhD, Nabiha H. Saifee, MD, PhD, Aaron A. R. Tobian, MD, PhD, Jonathan Waters, MD, Nicole D. Zantek, MD, PhD, and Monica B. Pagano, MD) and members appointed by professional national and international organizations: Lewis J. Kaplan, MD (Society of Critical Care Medicine), Jonathan Waters, MD (American Society of Anesthesiologists and Society for Advancement of Patient Blood Management), Yulia Lin, MD (American Society of Hematology), Erica M. Wood, MD (International Society of Blood Transfusion), Cynthia So-Osman, MD, PhD (European Hematology Association), Katerina Pavenski, MD (International Collaboration for Transfusion Medicine Guidelines), and Stacey Valentine, MD, MPH (Pediatric Critical Care Transfusion and Anemia Expertise Initiative/Pediatric Critical Care Blood Research Network). Specialties represented included pathologists and hematologists (most with subspecialty expertise in transfusion medicine), anesthesiologists, pediatricians (Simon J. Stanworth, MD, DPhil, and Stacey Valentine, MD, MPH), internists (Jeffrey L. Carson, MD, and Micah T. Prochaska, MD), and critical care medicine physicians and trauma and acute care surgeons (Lewis J. Kaplan, MD). Chairs: Jeffrey L. Carson, MD, Department of Medicine, Rutgers Robert Wood Johnson Medical School; Chair, AABB CTMC committee: Monica B. Pagano, MD, Department of Laboratory Medicine and Pathology, University of Washington; Simon J. Stanworth, MD, Department of Haematology, Oxford University Hospitals NHS Trust, NHSBT, and University of Oxford; Stacey Valentine, MD, Department of Pediatrics, UMASS Medical Center. Members: Sara Bakhtary, MD, Department of Laboratory Medicine, University of California–San Francisco, AABB CTMC member; Claudia S. Cohn, MD, PhD, Department of Laboratory Medicine and Pathology, University of Minnesota, AABB chief medical officer; Brenda J. Grossman, MD, MPH, Department of Pathology and Immunology, Washington University School of Medicine, AABB CTMC member; Gaurav K. Gupta, MD, PhD, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, AABB CTMC member; Aaron S. Hess, MD, PhD, Departments of Anesthesiology and Pathology and Laboratory Medicine, University of Wisconsin–Madison, AABB CTMC member; Jessica L. Jacobson, MD, Department of Pathology, New York University Grossman School of Medicine and NYC Health + Hospitals/Bellevue, AABB CTMC member; Lewis J. Kaplan, MD, Department of Surgery, Division of Trauma, Surgical Critical Care and Surgical Emergencies, Perelman School of Medicine, University of Pennsylvania, Society of Critical Care Medicine, representative; Yulia Lin, MD, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, American Society of Hematology, representative; Ryan A. Metcalf, MD, Department of Pathology, University of Utah, AABB CTMC member; Colin H. Murphy, MD, Pathology Associates of Albuquerque, Albuquerque, New Mexico, AABB CTMC member; Katerina Pavenski, MD, Department of Laboratory Medicine and Pathobiology, University of Toronto and St. Michael’s Hospital–Unity Health Toronto, International Collaboration for Transfusion Medicine Guidelines, representative; Micah T. Prochaska, MD, Department of Medicine, University of Chicago, AABB CTMC member; Jay S. Raval, MD, Department of Pathology, University of New Mexico, AABB CTMC member; Eric Salazar, MD, PhD, Department of Pathology and Laboratory Medicine, UT Health San Antonio, AABB CTMC member; Nabiha H. Saifee, MD, PhD, Department of Laboratory Medicine and Pathology, Seattle Children’s Hospital, AABB CTMC member; Aaron A. R. Tobian, MD, PhD, Department of Pathology, Johns Hopkins University, AABB president-elect; Cynthia So-Osman, MD, PhD, Department of Unit Transfusion Medicine (UTG), Sanquin Blood Bank, Amsterdam, the Netherlands, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands, European Hematology Association SWG Transfusion, representative; Jonathan Waters, MD, Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, American Society of Anesthesiologists, representative, Society for Advancement of Patient Blood Safety, representative, AABB CTMC member; Erica M. Wood, MD, Department of Haematology, Monash Health, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia, International Society of Blood Transfusion, representative; Nicole D. Zantek, MD, PhD, Department of Laboratory Medicine and Pathology, University of Minnesota, AABB CTMC member. Patient partner: Allan Dubon, MLS, ThermoFisher Scientific. Consultants: Gordon Guyatt, MD, Department of Clinical Epidemiology and Biostatistics and Department of Medicine, McMaster University; Jane Dennis, PhD, Cochrane Injuries Group, London School of Hygiene and Tropical Medicine. AABB staff: Sharon Carayiannis, MT (ASCP)HP, vice president, Science and Practice; Ekaterina Torres, BS, meetings and awards manager.

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 credit toward the CME of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close